“There are a lot of studies that have shown that e-cigarette use may be associated with inflammation in the lungs and also may cause severe lung injury in certain users, causing a condition called e-cigarette or vaping use-associated lung injury,” says Robert Vassallo, M.D., a Mayo Clinic pulmonologist and critical care specialist, and co-author of the study. “Our research was not designed to test whether e-cigarette use increases the risk of acquiring COVID infection, but it clearly indicates that symptom burden in patients with COVID-19 who vape is greater than in those who do not vape.”
The uncertainties of the health effects of e-cigarette use are due in part to the variety of devices, ingredients in the vaping liquid, and use. Nonetheless, the study documented a significant difference in symptom frequency between those who vape and were COVID-19 positive and those who did not vape.
The increased inflammation of lung tissue promoted by COVID-19 infection and the inflammation induced by vaping may worsen the likelihood of systemic inflammation, with an associated increase in symptoms such as fever, myalgias, fatigue and headache, the study finds.
“During a pandemic with a highly transmissible respiratory pathogen like SARS-CoV-2 (the virus that causes COVID-19), it is highly advisable to reduce or stop vaping and e-cigarette use, and minimize the potential for increased symptoms and lung injury,” says Dr. Vassallo.
The study was supported in part by Mayo Clinic’s Department of Medicine, Division of General Internal Medicine, and by a Center for Clinical and Translational Science award from the National Center for Advancing Translational Sciences.
Dr. Vassallo reports receiving grant funding support from Pfizer Inc., Bristol-Myers Squibb Co. and Sun Pharmaceutical Industries Ltd. for research activities unrelated to this study. The authors report no other competing interests.
For more content like this, sign up for the Pulse newsletter here.